checkAd
    4D Molecular Therapeutics Aktie
    25,75
     
    USD
    +0,70 %
    +0,18 USD
    Letzter Kurs 21:04:13 Nasdaq
    25,75
     
    USD
    300 STK
    Geldkurs 21:02:54
    25,81
     
    USD
    400 STK
    Briefkurs 21:02:54
    ISIN: US35104E1001 · WKN: A2PS5P · SYM: FDMT · USA

    Neueste Nachrichten

    4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
    09.05.24 · globenewswire · 4D Molecular Therapeutics
    4DMT to Participate in Upcoming Investor Conference
    07.05.24 · globenewswire · 4D Molecular Therapeutics
    4DMT Announces Presentations at ARVO 2024 Annual Meeting
    01.05.24 · globenewswire · 4D Molecular Therapeutics
    4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
    28.03.24 · globenewswire · 4D Molecular Therapeutics
    4DMT to Participate in Upcoming Investor Conferences
    04.03.24 · globenewswire · 4D Molecular Therapeutics
    4DMT Reports Full Year 2023 Financial Results and Operational Highlights
    29.02.24 · globenewswire · 4D Molecular Therapeutics
    4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium 2024
    12.02.24 · globenewswire · 4D Molecular Therapeutics
    4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
    07.02.24 · globenewswire · 4D Molecular Therapeutics
    4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
    05.02.24 · globenewswire · 4D Molecular Therapeutics
    4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
    03.02.24 · globenewswire · 4D Molecular Therapeutics
    4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
    29.01.24 · globenewswire · 4D Molecular Therapeutics
    4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
    23.01.24 · globenewswire · 4D Molecular Therapeutics